G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges

G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges

Deciphering G-Protein-Coupled Receptor 119 Agonists as Promising Strategy against Type 2 Diabetes Using Systems Biology Approach

Structural Insight on GPR119 Agonist as Potential Therapy for Type II Diabetes: A Comprehensive Review

Frontiers Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales

Full article: GPR119 agonists for the treatment of type 2 diabetes: an updated patent review (2014-present)

GPR119 Agonists: A Novel Strategy for Type 2 Diabetes Treatment

Deciphering G-Protein-Coupled Receptor 119 Agonists as Promising Strategy against Type 2 Diabetes Using Systems Biology Approach

Cancers, Free Full-Text

Frontiers Structure of human GPR119-Gs complex binding APD597 and characterization of GPR119 binding agonists

Frontiers ZB-16, a Novel GPR119 Agonist, Relieves the Severity of Streptozotocin–Nicotinamide-Induced Diabetes in Rats

GPR119 agonists 2009–2011 Pharmaceutical Patent Analyst

GPR119 Agonists: A Novel Strategy for Type 2 Diabetes Treatment

G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges